ERBB2 and neoplasm: The distribution of adverse event reporting rates suggests that those patients treated with two or more HER2 inhibitors were more likely to report AEs for SOCs such as blood and lymphatic system disorders, infections and infestations, investigations, and neoplasms benign, malignant, and unspecified compared to monotherapy.